/MESO
MESO Stock - Mesoblast Limited
Healthcare|BiotechnologyNASDAQ
$19.48+4.73%
+$0.88 (+4.73%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.98
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.90
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-41.0%upside
Target: $11.49
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MESO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$19.29 – $19.67
TARGET (TP)$11.50
STOP LOSS$17.92
RISK/REWARD1:-5.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.76
52W High$22.00
52W Low$9.61
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $17.20M | $5.90M | $7.50M | $10.21M | $7.46M |
| Gross Profit | $12.07M | $-35,168,000 | $-47,421,000 | $-53,361,000 | $-78,275,000 |
| Gross Margin | 70.2% | -595.9% | -632.2% | -522.6% | -1049.8% |
| Operating Income | $-62,443,000 | $-84,147,000 | $-69,289,000 | $-80,574,000 | $-109,096,000 |
| Net Income | $-102,142,000 | $-87,956,000 | $-81,889,000 | $-91,347,000 | $-98,811,000 |
| Net Margin | -593.9% | -1490.3% | -1091.7% | -894.6% | -1325.3% |
| EPS | $-0.84 | $-0.89 | $-0.98 | $-1.30 | $-1.60 |
Company Overview
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
50%
Hold / Neutral
5
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
5 Bullish5 Neutral/Bearish
Price Targets
$8
Average Target
↓ 58.9% Downside
Now
$2
Low
$8
Average
$12
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 25th 2025 | Jefferies | Upgrade | Buy | - |
| July 18th 2025 | Jefferies | Downgrade | Hold | - |
| December 23rd 2024 | Jefferies | Downgrade | Hold | - |
| September 24th 2024 | Maxim Group | Upgrade | Buy | $12 |
| August 29th 2024 | Jefferies | Upgrade | Buy | - |
| July 23rd 2024 | Piper Sandler | Upgrade | Overweight | $11← $4 |
| August 31st 2023 | Jefferies | Upgrade | Buy | - |
| August 7th 2023 | Maxim Group | Downgrade | Hold | - |
| August 4th 2023 | Piper Sandler | Downgrade | Neutral | $2← $7 |
| August 4th 2023 | William Blair | Downgrade | Market Perform | - |
| March 9th 2023 | William Blair | Initiation | Outperform | $8 |
| December 6th 2022 | Jefferies | Downgrade | Hold | - |
| September 6th 2022 | Piper Sandler | Initiation | Overweight | $7 |
Earnings History & Surprises
MESOBeat Rate
44%
Last 16 quarters
Avg Surprise
-20.8%
EPS vs Estimate
Beats / Misses
7/9
Last 12 quarters
Latest EPS
$-0.21
Q3 2025
EPS Surprise History
Q3 23
+12.5%
$-0.28vs$-0.32
Q4 23
+7.7%
$-0.12vs$-0.13
Q1 24
+15.0%
$-0.34vs$-0.40
Q2 24
No data
Q3 24
+25.7%
$-0.26vs$-0.35
Q4 24
+9.7%
$-0.28vs$-0.31
Q1 25
+91.6%
$-0.02vs$-0.25
Q3 25
-6.4%
$-0.21vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q3 2025 | Sep 3, 2025 | $-0.20 | $-0.21 | -6.4% | ✗ MISS |
Q3 2025 | Sep 3, 2025 | $-0.20 | — | — | — |
Q2 2025 | Apr 30, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | $-0.25 | $-0.02 | +91.6% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q3 2024 | Jul 4, 2024 | $-0.35 | $-0.26 | +25.7% | ✓ BEAT |
Q2 2024 | Jun 27, 2024 | — | $-0.26 | — | — |
Q1 2024 | Mar 25, 2024 | $-0.40 | $-0.34 | +15.0% | ✓ BEAT |
Q4 2023 | Dec 26, 2023 | $-0.13 | $-0.12 | +7.7% | ✓ BEAT |
Q3 2023 | Aug 30, 2023 | $-0.32 | $-0.28 | +12.5% | ✓ BEAT |
Q2 2023 | May 25, 2023 | $-0.36 | $-0.26 | +27.8% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.30 | $-0.34 | -13.3% | ✗ MISS |
Q4 2022 | Nov 22, 2022 | $-0.20 | $-0.24 | -20.0% | ✗ MISS |
Q3 2022 | Aug 30, 2022 | $-0.10 | $-0.34 | -240.0% | ✗ MISS |
Q2 2022 | May 31, 2022 | $-0.16 | $-0.32 | -100.0% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.39 | $-0.40 | -3.7% | ✗ MISS |
Q4 2021 | Nov 23, 2021 | $-0.30 | $-0.34 | -13.3% | ✗ MISS |
Q3 2021 | Aug 31, 2021 | $-0.32 | $-0.34 | -6.3% | ✗ MISS |
Q2 2021 | Jun 2, 2021 | $-0.20 | $-0.44 | -120.0% | ✗ MISS |
Latest News
Reported Earlier, Mesoblast Announces ASH Presentation Of Independent Study Showing Remestemcel-L Superior To Ruxolitinib In SR-aGvHD Clinical Outcomes
📈 PositiveBenzinga•Dec 12, 2025, 08:27 AM
Jefferies Upgrades Mesoblast to Buy
📈 PositiveBenzinga•Nov 25, 2025, 01:39 PM•Also:
Reported Earlier, Mesoblast And BMT CTN Launch Pivotal Trial Of Ryoncil For Adults With Grade III IV Severe SR aGvHD
📈 PositiveBenzinga•Nov 21, 2025, 08:40 AM
Mesoblast Appoints James M O'Brien As Chief Financial Officer To Support Transition To Fully Integrated Commercial Organization
📈 PositiveBenzinga•Nov 17, 2025, 07:19 AM
Reported Earlier, Mesoblast Reports FDA Meeting Scheduled For December To Review Rexlemestrocel-L Opioid Reduction Outcomes
➖ NeutralBenzinga•Nov 5, 2025, 08:23 AM
Reported Sunday, Mesoblast Q1 Revenue Surges To $20.6M As Ryoncil Net Sales Jump 69% Driven By Wider Physician Adoption And Reimbursement
📈 PositiveBenzinga•Oct 20, 2025, 06:55 AM
Reported Earlier, Mesoblast Reports Ryoncil® Quarterly Revenue Of $21.9M, Up 66% Sequentially Following Strong Post-Launch Adoption And Reimbursement Gains
📈 PositiveBenzinga•Oct 7, 2025, 06:47 AM
Mesoblast shares are trading higher after the company announced that Ryoncil received J-Code from the United States Medicare & Medicaid Services, allowing the product to become easier to bill and pay for.
📈 PositiveBenzinga•Oct 3, 2025, 12:38 PM
Reported Earlier, Mesoblast's Ryoncil Receives CMS J-Code J3402 Activation Effective October 1 Enhancing Patient Access And Facilitating Broader Coverage
📈 PositiveBenzinga•Oct 3, 2025, 06:32 AM
Mesoblast Announces Allogeneic Cell Therapy Products From US Donors Are US Origin And Not Subject To Tariffs
📈 PositiveBenzinga•Sep 26, 2025, 06:13 AM
Mesoblast shares are trading higher after the company announced the commercial launch of Ryoncil.
📈 PositiveBenzinga•Sep 15, 2025, 12:54 PM
Reported Sunday, Mesoblast Showcases Strong Launch Of Ryoncil At Global Healthcare Conferences With Plans To Expand Indications And Advance Phase 3 Programs
📈 PositiveBenzinga•Sep 15, 2025, 06:22 AM
Reported Earlier, Mesoblast Enters Into Option To Issue Up To $50M Unsecured Convertible Notes With Key Shareholders
📈 PositiveBenzinga•Sep 4, 2025, 06:17 AM
Mesoblast shares are trading lower after the company reported worse-than-expected FY EPS results.
📉 NegativeBenzinga•Aug 29, 2025, 12:44 PM
Mesoblast FY EPS $(0.09) Misses $(0.05) Estimate, Sales $17.20M Up From $5.90M YoY
➖ NeutralBenzinga•Aug 29, 2025, 07:02 AM
Mesoblast, FDA agree on marketing application for cell therapy
📈 PositiveSeeking Alpha•Jul 1, 2025, 01:57 PM
Frequently Asked Questions about MESO
What is MESO's current stock price?
Mesoblast Limited (MESO) is currently trading at $19.48 per share. The stock has moved +4.73% today.
What is the analyst price target for MESO?
The average analyst price target for MESO is $11.50, based on 1 analyst.
What sector is Mesoblast Limited in?
Mesoblast Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MESO's market cap?
Mesoblast Limited has a market capitalization of $2.50 billion, making it a mid-cap company.
Does MESO pay dividends?
No, Mesoblast Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCOGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
EWTX
Edgewise Therapeutics, Inc.
$25.55
Mkt Cap: $2.7B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
GPCR
Structure Therapeutics Inc.
$64.94
Mkt Cap: $3.7B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
LQDA
Liquidia Corporation
$34.53
Mkt Cap: $3.0B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
QURE
uniQure N.V.
$23.99
Mkt Cap: $1.3B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to MESO for comparison